Med BioGene Posts 2009 Loss of $2.1M

Preparing for commercialization of its LungExpress Dx test, the company boosted R&D spending and trimmed general costs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories